Breaking News

Glenmark Launches Latanoprost Ophthalmic Solution

The product is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan Ophthalmic Solution, 0.005%.

Glenmark Pharmaceuticals Inc. USA has launched Latanoprost Ophthalmic Solution, a 0.005% (0.05 mg/mL) ophthalmic solution. This product is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan Ophthalmic Solution.

Marc Kikuchi, President & Business Head, North America, expressed excitement about the launch, stating that it marks the fourth ophthalmic product in Glenmark’s portfolio.

“This addition highlights our commitment to meeting market needs and providing quality solutions for our customers,” Kikuchi remarked.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters